Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mysimba for weight regain after bariatric surgery
NL-OMON58935Phase 4Not yet recruiting
- Sponsor
- Zuyderland
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of naltrexone + bupropion, bupropion and naltrexone in obesity and post-bariatric surgery weight regain (3 arms), sponsored by Zuyderland. Primary endpoints: Successful weight loss after 22 weeks and Dose response of Mysimba. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
naltrexone + bupropionbupropionnaltrexone
03
Conditions
obesitypost-bariatric surgery weight regain
Beyond the preview
Go deeper on NL-OMON58935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58935.